Compare AbCellera Biologics Inc (ABCL) vs iShares S&P GSCI Commodity-Indexed Trust ETF (GSG) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs iShares S&P GSCI Commodity-Indexed Trust ETF — how do they compare? AbCellera Biologics Inc trades at $7.25 (market cap $2.35B), while iShares S&P GSCI Commodity-Indexed Trust ETF trades at $29.86. The key difference: AbCellera Biologics Inc is trading nearer its 52-week high, iShares S&P GSCI Commodity-Indexed Trust ETF nearer its low. Which is the better fit depends on your goals.
| ABCL | GSG | |
|---|---|---|
Market Cap | $2.35B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $8.12 | $34.77 |
52-Week Low | $2.78 | $22.06 |
Enterprise Value | $1.99B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
GSG trades at $28.89, up 1.83% today, with a bullish technical signal but mixed moving averages and neutral oscillators. Recent news highlights institutional interest, with JPMorgan Chase increasing its stake by 224.3% in Q3 2025 (SEC filing, 2026-04-07). Commodity ETFs like GSG are gaining attention amid inflation fears and supply constraints, as noted by Zacks Investment Research (2026-04-07).
The outlook for GSG is supported by strong commodity market trends and institutional accumulation, but risks include volatility from geopolitical events and inflation shifts. Key support sits at $28, with resistance near $29. Wall Street sentiment is cautiously optimistic due to macroeconomic tailwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About iShares S&P GSCI Commodity-Indexed Trust ETF
GSG is a diversified commodity ETF that tracks the S&P GSCI Total Return Index. It provides exposure to a broad basket of futures, including energy, metals, and agriculture, with a significant weighting toward the energy sector.
Read more on GSG →
